Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Relmada Therapeutics CEO Sergio Traversa Reported Purchase Of 100,000 Shares @ Avg Price Of $3.87/Share In Form 4 Filing On Wednesday

Author: Charles Gross | January 31, 2024 07:57pm

Posted In: RLMD